Estrogen receptor beta

Hypogonadism Market Spotlight Report 2021: Clinical Trials, Regulatory Events, Licensing and Acquisitions, and Drug-specific Revenue Forecasts - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 27, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Hypogonadism, Estrogen receptor beta, Overalls, Estrogen receptor alpha, Testosterone undecanoate, Aromatase, Epidemiology, GlaxoSmithKline, PDUFA, Clinical trial, Probability, AbbVie, Acquisition, NDA, Pharmaceutical industry, Birth control, Medical device

This Market Spotlight report covers the Hypogonadism market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, key upcoming and regulatory events, probability of success, patent information, epidemiology, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Points: 
  • This Market Spotlight report covers the Hypogonadism market, comprising key marketed and pipeline drugs, recent events and analyst opinion, clinical trials, key upcoming and regulatory events, probability of success, patent information, epidemiology, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
  • The approved drugs in the hypogonadism space target androgen receptors, estrogen receptor alpha, and estrogen receptor beta.
  • There are almost equal proportions of clinical trials for hypogonadism across Phase I-IV, with 51% in Phase I-II, and 49% in Phase III-IV.
  • AbbVie leads industry sponsors with the highest overall number of clinical trials for hypogonadism, followed by GlaxoSmithKline.

Insights on the Endocrine Disruption Screening Global Market to 2028 - Growing Prevalence of Endocrine Disorders is Driving the Industry - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 12, 2022
Health, Biotechnology, CAGR, Melanoma, Breast cancer, Patient, Non-Hodgkin lymphoma, Bouquet (EP), Biotechnology, Incidence, Kidney cancer, Prostate cancer, COVID-19, Endometrial cancer, National Institute of Cancer Research and Hospital, Growth, Leukemia, Thyroid cancer, Solution, National, Survivor, Cancer, Pancreatic cancer, National Institute, Time, Bladder cancer, Industry, Diabetes, Food industry, Degenerative disease, Cosmetics, Chemical industry, AR, Prevalence, Lung cancer, Incineration, Colon, Conditional sentence, Estrogen receptor beta, Animal, Medical imaging, Fine chemical, Marketing

The "Endocrine Disruption Screening Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Endocrine Disruption Screening Market Forecast to 2028 - COVID-19 Impact and Global Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The market growth is attributed to factors such as the increasing prevalence of endocrine disorders and the rising incidence of diabetes.
  • The rising burden of cancer patients and especially hormone-related cancers patients will flourish the demand for endocrine disruption screening across the world.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.